RxDoctor Payments Data

David Furman, DO

Family Medicine · Fort Wayne, INNPI 1831548510

Payments from drug & device makers

$4,037in general payments, 2019–2025

Across 252 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$617
  • AstraZeneca$601
  • Novo Nordisk$416
  • Sanofi-aventis U.S. LLC$353
  • GSK$262
  • Pfizer$237
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,037100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,037 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$7,300
Medicare patients
47
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin12$20,495
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,898
MounjaroTirzepatide15$18,030
Nano 2nd Gen Pen NeedlePen Needle, Diabetic15$803
Albuterol Sulfate HfaAlbuterol Sulfate33$651
Pregabalin14$581
Tamsulosin Hcl57$477
Hydroxyzine Hcl19$461
Atorvastatin Calcium62$386
Bupropion XlBupropion Hcl25$321
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$215
Rosuvastatin Calcium31$213
Levothyroxine Sodium27$172
Metformin Hcl39$120
Losartan Potassium23$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$130$20,49512 claims
GSKTrelegy Ellipta$262$18,89819 claims
Lilly USA, LLCMounjaro$222$18,03015 claims
Almatica Pharma LLCSertraline Hcl$16$10524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →